Collaboration, Licensing and Other Arrangements - Additional Information (Detail) - USD ($)		1 Months Ended		3 Months Ended		6 Months Ended		12 Months Ended
		Dec. 31, 2022	May 31, 2018	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Feb. 28, 2023
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue - current		$ 1,733,000		$ 3,489,000		$ 3,489,000		$ 1,733,000
Deferred revenue - non-current		37,684,000		60,248,000		60,248,000		37,684,000
Total revenue from UT				48,611,000	$ 18,894,000	89,237,000	$ 30,886,000
Collaborations and services
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT				11,211,000	5,868,000	22,597,000	8,034,000
AFREZZA product sales
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT				18,345,000	12,722,000	35,907,000	22,548,000
United Therapeutics Corporation
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT				30,230,000	5,697,000	53,257,000	7,739,000
United Therapeutics Corporation | Manufacturing Services
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Funding for development of alternative manufacturing processes		2,300,000
United Therapeutics Corporation | Commercialization and Continuous Improvement Activities
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Funding for capital improvements		39,500,000
Thirona Bio, Inc.
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Minimum amount to expended									$ 1,100,000
Collaboration and License Agreement | United Therapeutics Corporation
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total anticipated cash flows	[1]	722,300,000						722,300,000
Deferred revenue		37,900,000		62,300,000		62,300,000		37,900,000
Deferred revenue - current		1,600,000		3,300,000		3,300,000		1,600,000
Deferred revenue - non-current		36,300,000		59,000,000		59,000,000		36,300,000
Collaboration and License Agreement | United Therapeutics Corporation | Manufacturing Services
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total anticipated cash flows		722,300,000						722,300,000
Allocated transaction price		220,800,000
Collaboration and License Agreement | United Therapeutics Corporation | Manufacturing Services | Transaction Price For The Contractual Obligations
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total anticipated cash flows		120,000,000						120,000,000
Collaboration and License Agreement | United Therapeutics Corporation | Next-Gen R&D Services | Transaction Price For The Performance Obligations
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total anticipated cash flows		$ 602,300,000						602,300,000
Commercial Supply Agreement | United Therapeutics Corporation
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT				10,933,000	4,695,000	22,097,000	5,879,000
Supply and Distribution Agreement | AFREZZA product sales | Biomm
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT						0		$ 0
License and Distribution Agreement | Cipla Ltd
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue				1,400,000		1,400,000
Deferred revenue - current				100,000		100,000
Deferred revenue - non-current				1,300,000		1,300,000
Marketing and distribution agreement date			2018-05
License and Distribution Agreement | Collaborations and services | Cipla Ltd
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT				$ 36,000	$ 36,000	$ 73,000	$ 73,000

[1] The total anticipated cash flow includes a transaction price of $120.0 million for the contractual obligations under the CSA for the Manufacturing Services and the Next-Gen R&D Services performance obligations and $602.3 million for future supply of Tyvaso DPI over the remaining term of the CSA.